PDL Biopharma's current assets is $310M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2020), PDLI shows a current assets of $310M. That compares with $410M in the prior-year period — down 22.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PDLI's current assets is now $310M (was $410M) — a 22.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.
Tracking PDLI's current assets over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $310M That compares with $410M in the prior-year period — down 22.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current assets page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $310M) with ownership activity and broader fundamentals.
PDL Biopharma's current assets is $310M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.